🟢 BioXcel Therapeutics is trading 11.33% up in pre-market after positive Phase 3 SERENITY At-Home data

BioXcel Therapeutics is trading 11.33% up at $0.89 in pre-market after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19, 2026.

• Analysts raised fair-value estimates to approximately $18.33 from $14, supporting bullish sentiment.
• Trading activity is elevated in pre-market.
• BioXcel Therapeutics faces an August 21, 2026 financing deadline requiring repayment or alternative capital arrangements.